Results 111 to 120 of about 75,992 (272)

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Perioperative nivolumab in resectable lung cancer [PDF]

: BACKGROUND Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC).
Karaseva, Nina, Ito, Hiroyuki, Cornelissen, Robin, Taube, Janis M., Provencio Pulla, Mariano, Sepesi, Boris, Spicer, Jonathan D., Bohnet, Sabine, Awad, Mark M., Cascone, Tina, Tanaka, Fumihiro, Petruzelka, Lubos B., de Muniz Koch, Ludmila Oliveira, Pujol, Jean-Louis, Wu, Lin, He, Jie, Erdmann, Cinthya Coronado, Moiseyenko, Fedor V., Blum, Steven I., Gao, Yang, Kuzdzal, Jaroslaw, Meadows-Shropshire, Stephanie, Havel, Libor, Alexandru, Aurelia, Lu, Shun, Ciuleanu, Tudor-Eliade, Sathyanarayana, Padma, Janssens, Annelies, Watanabe, Yasutaka   +28 more
core   +2 more sources

Patient‐derived organoid‐immune co‐cultures integrated with multi‐omics reveal immunotherapy resistance mechanisms in urothelial carcinoma

iMeta, EarlyView.
Immunotherapy resistance presents a formidable challenge in tumor biology. While fibroblast growth factor receptor 3 (FGFR3) serves as a pivotal oncogenic driver in a multitude of cancers, the exploration of its role in immune checkpoint inhibitor (ICI) resistance remains scarce, thus impeding a deeper understanding of the tumor immune microenvironment
Shan Jiang, Yuxuan Song, Yun Peng, Ran Yan, Yunze Niu, Baoqiang Chen, Jiaxing Lin, Jilin Wu, Shixiang Wang, Yiqing Du, Caipeng Qin, Yihan Lin, Tao Xu   +12 more
wiley   +1 more source

Enhanced peripheral blood mononuclear cell lipid metabolism drives poor immunotherapy response via ferroptotic stress‐induced T cell exhaustion in hepatocellular carcinoma

Interdisciplinary Medicine, EarlyView.
Integrated multi‐omics reveals that CD36‐mediated lipid overload in PBMCs drives T cell exhaustion via sub‐lethal ferroptotic stress and AKT suppression. This systemic metabolic signature serves as a robust predictor of immunotherapy response in HCC, suggesting that modulating lipid metabolism can rescue immune fitness.
Ying Zhu, Zhouyu Ning, Yong Deng, Changjing Huang, Hui Li, Yun Sun, Zhiqiang Meng   +6 more
wiley   +1 more source

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC. Case Presentation A 71‐year‐old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC ...
Shimasaki S, Yamamoto S, Iguchi M, Yamashita E, Atagi K, Shiba Y, Fukata S, Satake H, Karashima T, Inoue K.   +9 more
europepmc   +2 more sources

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Introduction Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer

Journal of Cancer Research and Practice
Nivolumab is now preferred as first-line and second-line treatment for advanced esophageal cancer, while regorafenib improves survival in refractory gastroesophageal cancer.
Mei-Chen Lin, Li-Yuan Bai, Shih-Peng Yeh, Chang-Fang Chiu, Ming-Yu Lien   +4 more
doaj   +1 more source

A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis

, 2017
Nivolumab (Opdivo) approval for the treatment of non-small cell lung cancer (NSCLC) prompts recognition of its future use in various cancers. Although rare, occurring in 1% to 3% of treated cases, nivolumab along with other immune checkpoint inhibitors ...
Sowmya Nanjappa, Jacqueline Weslow, Stephanie L. Porcella, Kaja Richard   +3 more
core   +1 more source